Search

for
Search:

Research

5 / 957 results

research Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata

13 citations , September 2022 in “Frontiers in immunology”

This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.

research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial

2 citations , September 2023 in “Journal of the American Academy of Dermatology”

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

2 citations , September 2024 in “Journal of the American Academy of Dermatology”

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review

January 2026

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index

research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index

September 2019 in “Journal of Investigative Dermatology”

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

View more "jak1 3 inhibition" in research →

Learn

2 / 801 results

learn Tofacitinib

a JAK inhibitor for alopecia areata and other autoimmune conditions

learn Baricitinib

JAK inhibitor that reduces inflammation and immune attacks on hair follicles, leading to potential hair regrowth, especially in alopecia areata cases

View more "jak1 3 inhibition" in learn →

Experts

6 / 20 results

All 20 expert results →

Clinics

2 / 2 results

Community Join

— no results

Try a deeper search in community →

Search

for
Search:

Research

research Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata

research 41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial

research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials

research Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review

research 170 Forecasting Phase 3 Dose-Response for Abrocitinib, an Oral Janus Kinase 1 Selective Inhibitor, Using Investigator’s Global Assessment and Eczema Area and Severity Index

Learn

learn Tofacitinib

learn Baricitinib

Experts

Jak, 5+ years experience, accredited SMP specialist

Jack, SMP Certified Trainer

Jack, Certified SMP practitioner

Dr. Jack Yeoman, MD

Jackie Apostol-Pizzuti

Jackie Barboza

Clinics

Community Join